Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas. The company was founded in 2020 and is headquartered in Warren, New Jersey.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/23/2025 14:17 PDT] Tevogen Bio Holdings Inc. (NASDAQ:tvgn), Up By 100% ($1.11) After BUYINS.NET SqueezeTrigger Report Released on Tuesday, April 15th 2025 at a Price of $1.108.
• [05/13/2025 10:10 PDT] Tevogen Bio Holdings Inc. (NASDAQ:tvgn), Up By 100% ($1.01) From $1.01 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/12/2025 10:11 PDT] Tevogen Bio Holdings Inc. (NASDAQ:tvgn), Up By 100% ($1.06) After BUYINS.NET SqueezeTrigger Report Released on Wednesday, May 7th 2025 at a Price of $1.055.
• [05/07/2025 08:16 PDT] tvgn SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [04/24/2025 07:34 PDT] tvgn Expected to Trade Up After Bullish Patterns Develop
• [04/15/2025 14:55 PDT] tvgn SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [04/07/2025 08:02 PDT] tvgn Expected to Trade Down After Bearish Patterns Develop